Where does Abionyx Pharma SA rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Abionyx Pharma SA ranks #30,724 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Abionyx Pharma SA hold?

Abionyx Pharma SA holds 8 US utility patents granted between 2023 and 2025, spanning 7 technology areas.

What is Abionyx Pharma SA's Innovation Score?

Abionyx Pharma SA has an Innovation Score of 48.2 out of 100 (top 17% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Abionyx Pharma SA's patent grant rate increasing or decreasing?

Insufficient historical data is available to calculate a velocity trend for Abionyx Pharma SA.

What does claim depth mean for Abionyx Pharma SA's patents?

Abionyx Pharma SA's patents average 18.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Abionyx Pharma SA patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Abionyx Pharma SA

Q: What technology areas does Abionyx Pharma SA focus on?

Abionyx Pharma SA's top technology area is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations) with 8 patents. Grants appear in 7 CPC subclasses total.

USPTO PatentsView assignee record - 8 granted patents across 7 technology areas, recorded in grant years 2023–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Abionyx ranks #30,724 of 49,997 tracked US assignees by granted-patent volume, with 8 patents across 7 technology areas.

#30,724
of 49,997 US assignees by volume: Top 17%
by Innovation Score (48.2/100): 18.8
avg claims per patent

USPTO PatentsView assignee plate

Corpus R30724 · Foreign Corporation #30,724 · 8 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · SPAN-YRS · BOOK-RICH

GRANTS-MICRO 8 grants
MID-PACK #30,724/49,997
PHOTO-FINISH ABB HV Cables…
CPC-NARROW A61P · 7 areas
INNOV-PAR 48.2/100
CLAIMS-RICH 18.8 claims/avg
TYPE-FRNCORP Foreign Corp
SPAN-YRS 2023–2025 · 3y
BOOK-RICH 9/10 fields

Nearest grant-volume peer: ABB HV Cables (SWITZERLAND) GMBH (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Abionyx Pharma · this assignee

48
3D Lighting… · lowest

7

What this shows Abionyx's Innovation Score is 48.2/100 (top 17% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Abionyx's grants concentrate

Abionyx Pharma SA is a focused PatentsView assignee: 7 CPC subclasses with 100% of grants classified under A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations). Peak complete grant year is 2023 (3 grants) versus a trough of 2 in 2024. By volume, Abionyx sits between ABB HV Cables (SWITZERLAND) GMBH and Actega North America Technologies, Inc..

Abionyx's three-year grant acceleration

Abionyx Pharma SA shows 5 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

ABB HV Cables (Sw…

8
ABC Fintech

8
ABC IP

8
Aber Instruments

8
Absolicon Solar C…

8
Acme Worldwide En…

8
Acrox

8
Actega North Amer…

8
Abionyx Pharma ◀

8

What this shows Abionyx holds 8 patents at rank #30,723, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Abionyx

By rank, the assignees closest to #30,723 in granted patent volume.

Leaders in A61P (Specific Therapeutic Activity OF Chemical Compounds OR Me…)

Other assignees with the most granted patents in Abionyx's primary technology class.

Abionyx's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

48 Top 17% higher than 83% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2023–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2023–2019 baseline. Full figures in the table below.

View data table

Abionyx Pharma SA patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2023	3	37.5%
2024	2	25.0%
2025partial year	3	37.5%

Which technologies does Abionyx Pharma SA patent most?

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 8

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 6

C07K - Peptides 5

C07D - Heterocyclic Compounds 2

C07B - General Methods OF Organic CHEMISTRY; Apparatus Therefor 2

C07C - Acyclic OR Carbocyclic Compounds 2

Y10T - Technical Subjects Covered BY Former US Classification 2

Top 7 of 7 technology areas

Where it ranks

Overall rank by patents

#30,724

of 49,997 tracked assignees

Innovation Score

48.2 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Abionyx Pharma SA's patent record in context - here's where to go next.

Abionyx Pharma SA's lead technology class is A61P (Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations), 100% of its portfolio - see every assignee active in that class. Explore A61P
Ranked #30,724 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Abionyx Pharma SA against ABB HV Cables (SWITZERLAND) GMBH, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 48.2/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.